Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PFE Stock Summary
Top 10 Correlated ETFs
PFE
In the News
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
5 Absolutely Best Dividend Stocks Yielding Over 5%
ALERT: 5.25% Yield Is 8x National Average (Sponsored) Robinhood Gold just rolled out a wild 5.25% APY yield for members, a whopping 8x the national average and way better than treasuries.
The 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months
Wise investors know that it isn't prudent to chase 100% returns within a period as short as 12 months. Playing the long game is the way to win when investing in the stock market.
Harnessing AI for Drug Discovery: Top 3 Stocks to Watch
Artificial intelligence (AI) spans above and beyond today's popular large language models (LLMs). OpenAI's ChatGPT-4 Turbo or even Anthropic's Claude 3 make for an impressive assistant for everyday tasks.
One AI/Healthcare Stock to Buy Today
Where to invest today according to our three experts
Stock Market Looking Dangerous – 6 Safe Large Cap Dividend Blue Chips
ALERT: Today Could Be Your Best Shot At Early Retirement (Sponsored) If you want to retire before 65, pay attention.
Buffett's Backdoor Buys: 3 Stocks His Secret Portfolio Is Quietly Accumulating
Warren Buffett stocks can teach you a thing or two about investing. Warren Buffett's annual shareholders letter to Berkshire Hathaway (NYSE: BRK-A )(NYSE: BRK-B ) investors outlines what he's done the past year and often why.
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?
Cathie Wood's Ark Genomic Innovation ETF has exited its position in Pfizer. Wood is likely disappointed with Pfizer's stock performance and its obesity drug setbacks.
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.
7 Stocks That Will Make Your Friends Green with Envy
There are some stocks to make friends envious for March this year. These companies have impressive growth prospects and strong fundamentals that position them for potential outperformance.
PFE Financial details
PFE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 9.29 | 7.54 | 14.51 | 17.89 | 10.37 | |
Net income per share | 2.92 | 1.26 | 3.92 | 5.59 | 0.38 | |
Operating cash flow per share | 2.26 | 2.59 | 5.82 | 5.22 | 1.54 | |
Free cash flow per share | 1.79 | 2.09 | 5.33 | 4.64 | 0.85 | |
Cash per share | 1.77 | 2.2 | 5.55 | 4.05 | 2.25 | |
Book value per share | 11.34 | 11.38 | 13.78 | 17.06 | 15.77 | |
Tangible book value per share | -5.49 | -2.62 | 0.56 | 0.21 | -7.69 | |
Share holders equity per share | 11.34 | 11.38 | 13.78 | 17.06 | 15.77 | |
Interest debt per share | 9.65 | 7.15 | 6.84 | 6.44 | 13.25 | |
Market cap | 207B | 204.48B | 330.74B | 287.35B | 162.46B | |
Enterprise value | 257.84B | 240.97B | 365.79B | 321.81B | 234.65B | |
P/E ratio | 12.72 | 29.13 | 15.05 | 9.16 | 76.67 | |
Price to sales ratio | 4 | 4.88 | 4.07 | 2.86 | 2.78 | |
POCF ratio | 16.44 | 14.2 | 10.15 | 9.82 | 18.67 | |
PFCF ratio | 20.71 | 17.61 | 11.07 | 11.04 | 33.9 | |
P/B Ratio | 3.28 | 3.23 | 4.28 | 3 | 1.83 | |
PTB ratio | 3.28 | 3.23 | 4.28 | 3 | 1.83 | |
EV to sales | 4.98 | 5.75 | 4.5 | 3.21 | 4.01 | |
Enterprise value over EBITDA | 13.06 | 17.13 | 12.82 | 7.37 | 22.29 | |
EV to operating cash flow | 20.48 | 16.73 | 11.23 | 11 | 26.97 | |
EV to free cash flow | 25.8 | 20.75 | 12.25 | 12.36 | 48.96 | |
Earnings yield | 0.08 | 0.03 | 0.07 | 0.11 | 0.01 | |
Free cash flow yield | 0.05 | 0.06 | 0.09 | 0.09 | 0.03 | |
Debt to equity | 0.83 | 0.61 | 0.48 | 0.36 | 0.81 | |
Debt to assets | 0.31 | 0.25 | 0.2 | 0.18 | 0.32 | |
Net debt to EBITDA | 2.57 | 2.59 | 1.23 | 0.79 | 6.86 | |
Current ratio | 0.88 | 1.35 | 1.4 | 1.22 | 0.91 | |
Interest coverage | 9.62 | 7.34 | 19.24 | 32.33 | 1.79 | |
Income quality | 0.77 | 2.05 | 1.45 | 0.93 | 4.08 | |
Dividend Yield | 0.04 | 0.04 | 0.03 | 0.03 | 0.06 | |
Payout ratio | 0.49 | 1.2 | 0.4 | 0.29 | 4.36 | |
Sales general and administrative to revenue | 0.23 | 0.23 | 0.13 | 0.11 | 0 | |
Research and developement to revenue | 0.17 | 0.22 | 0.17 | 0.11 | 0.18 | |
Intangibles to total assets | 0.56 | 0.51 | 0.41 | 0.48 | 0.59 | |
Capex to operating cash flow | -0.21 | -0.19 | -0.08 | -0.11 | -0.45 | |
Capex to revenue | -0.05 | -0.07 | -0.03 | -0.03 | -0.07 | |
Capex to depreciation | -0.43 | -0.58 | -0.52 | -0.64 | -0.62 | |
Stock based compensation to revenue | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
Graham number | 27.3 | 17.99 | 34.89 | 46.34 | 11.54 | |
ROIC | 0.12 | 0.1 | 0.2 | 0.27 | 0.05 | |
Return on tangible assets | 0.22 | 0.09 | 0.21 | 0.31 | 0.02 | |
Graham Net | -14.55 | -11.9 | -10.11 | -11.26 | -19.68 | |
Working capital | -4.5B | 9.15B | 17.02B | 9.12B | -4.46B | |
Tangible asset value | -30.58B | -14.58B | 3.11B | 1.17B | -43.4B | |
Net current asset value | -71.24B | -55.69B | -44.32B | -50.03B | -93.88B | |
Invested capital | 0.83 | 0.61 | 0.48 | 0.36 | 0.81 | |
Average receivables | 11.73B | 11.63B | 13.47B | 15.14B | 12.85B | |
Average payables | 4.45B | 4.26B | 4.94B | 6.19B | 6.76B | |
Average inventory | 7.9B | 8.16B | 8.55B | 9.02B | 9.59B | |
Days sales outstanding | 85.12 | 97.49 | 70.7 | 52.86 | 69.74 | |
Days payables outstanding | 150.73 | 180.95 | 66.06 | 72.36 | 83.84 | |
Days of inventory on hand | 295.85 | 337.87 | 107.28 | 95.45 | 127.31 | |
Receivables turnover | 4.29 | 3.74 | 5.16 | 6.91 | 5.23 | |
Payables turnover | 2.42 | 2.02 | 5.53 | 5.04 | 4.35 | |
Inventory turnover | 1.23 | 1.08 | 3.4 | 3.82 | 2.87 | |
ROE | 0.26 | 0.11 | 0.28 | 0.33 | 0.02 | |
Capex per share | -0.47 | -0.5 | -0.48 | -0.58 | -0.69 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-04-02 | 2023-07-02 | 2023-10-01 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 4.33 | 3.24 | 2.26 | 2.34 | 2.52 | |
Net income per share | 0.89 | 0.98 | 0.41 | -0.42 | -0.59 | |
Operating cash flow per share | 1.53 | 0.22 | -0.21 | 0.61 | 0.93 | |
Free cash flow per share | 1.35 | 0.01 | -0.38 | 0.47 | 0.74 | |
Cash per share | 4.05 | 3.54 | 7.93 | 7.83 | 2.25 | |
Book value per share | 17.04 | 17.92 | 17.54 | 17.17 | 15.76 | |
Tangible book value per share | 0.21 | 1.38 | 1.12 | 0.97 | -7.68 | |
Share holders equity per share | 17.04 | 17.92 | 17.54 | 17.17 | 15.76 | |
Interest debt per share | 6.27 | 6.43 | 11.66 | 11.39 | 12.95 | |
Market cap | 287.71B | 232.97B | 206.93B | 191.63B | 162.58B | |
Enterprise value | 322.17B | 266.69B | 269.63B | 252.07B | 234.77B | |
P/E ratio | 14.4 | 10.51 | 22.23 | -20.01 | -12.15 | |
Price to sales ratio | 11.84 | 12.74 | 16.25 | 14.48 | 11.41 | |
POCF ratio | 33.53 | 192.06 | -171.15 | 55.45 | 31.03 | |
PFCF ratio | 37.95 | 3.15K | -97.47 | 72.42 | 38.75 | |
P/B Ratio | 3.01 | 2.31 | 2.09 | 1.98 | 1.83 | |
PTB ratio | 3.01 | 2.31 | 2.09 | 1.98 | 1.83 | |
EV to sales | 13.26 | 14.59 | 21.17 | 19.05 | 16.48 | |
Enterprise value over EBITDA | 42.6 | 33.89 | 73.85 | -147.84 | 3.05K | |
EV to operating cash flow | 37.54 | 219.86 | -223.02 | 72.94 | 44.8 | |
EV to free cash flow | 42.5 | 3.6K | -127.01 | 95.27 | 55.95 | |
Earnings yield | 0.02 | 0.02 | 0.01 | -0.01 | -0.02 | |
Free cash flow yield | 0.03 | 0 | -0.01 | 0.01 | 0.03 | |
Debt to equity | 0.36 | 0.36 | 0.66 | 0.66 | 0.81 | |
Debt to assets | 0.18 | 0.18 | 0.3 | 0.3 | 0.32 | |
Net debt to EBITDA | 4.56 | 4.29 | 17.18 | -35.45 | 937.51 | |
Current ratio | 1.22 | 1.37 | 2.12 | 2.38 | 0.91 | |
Interest coverage | 20.55 | 20.07 | 4.09 | -4.7 | -2.32 | |
Income quality | 1.72 | 0.22 | -0.52 | -1.44 | -1.57 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.45 | 0.42 | 0.99 | -0.97 | -0.69 | |
Sales general and administrative to revenue | 0.08 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.15 | 0.14 | 0.21 | 0.2 | 0.19 | |
Intangibles to total assets | 0.48 | 0.48 | 0.42 | 0.43 | 0.59 | |
Capex to operating cash flow | -0.12 | -0.94 | 0.76 | -0.23 | -0.2 | |
Capex to revenue | -0.04 | -0.06 | -0.07 | -0.06 | -0.07 | |
Capex to depreciation | -0.66 | -0.77 | -0.58 | -0.52 | -0.63 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 18.46 | 19.92 | 12.75 | 12.8 | 14.49 | |
ROIC | 0.05 | 0.04 | 0.01 | -0.01 | -0.01 | |
Return on tangible assets | 0.05 | 0.05 | 0.02 | -0.02 | -0.04 | |
Graham Net | -11.25 | -10.72 | -11.2 | -10.67 | -19.66 | |
Working capital | 9.12B | 13.52B | 38.7B | 42.88B | -4.46B | |
Tangible asset value | 1.17B | 7.76B | 6.32B | 5.45B | -43.4B | |
Net current asset value | -50.03B | -44.3B | -47.53B | -43.8B | -93.88B | |
Invested capital | 0.36 | 0.36 | 0.66 | 0.66 | 0.81 | |
Average receivables | 16.57B | 13.42B | 11.27B | 10.66B | 11.13B | |
Average payables | 6.54B | 6.47B | 6.1B | 5.71B | 6.02B | |
Average inventory | 9.25B | 9.26B | 9.93B | 10.26B | 10.2B | |
Days sales outstanding | 53.83 | 60.58 | 72.31 | 75.4 | 70.6 | |
Days payables outstanding | 63.52 | 91.13 | 119.11 | 45.31 | 70.29 | |
Days of inventory on hand | 83.78 | 142 | 201.94 | 86.61 | 106.73 | |
Receivables turnover | 1.67 | 1.49 | 1.24 | 1.19 | 1.27 | |
Payables turnover | 1.42 | 0.99 | 0.76 | 1.99 | 1.28 | |
Inventory turnover | 1.07 | 0.63 | 0.45 | 1.04 | 0.84 | |
ROE | 0.05 | 0.05 | 0.02 | -0.02 | -0.04 | |
Capex per share | -0.18 | -0.2 | -0.16 | -0.14 | -0.18 |
PFE Frequently Asked Questions
What is Pfizer Inc. stock symbol ?
Pfizer Inc. is a US stock , located in New york of Ny and trading under the symbol PFE
Is Pfizer Inc. buy or a sell ?
31 stock analysts have 31 predictions with a medium analyst target price of $55.98. The lowest prediction is $20 and the highest is $141.39
What is PFE stock prediction ?
With a median analyst target price of $45, 1 stock analysts have made 1 forecasts in last 90 days. $45 is the lowest and $45 is the greatest projection.
What is Pfizer Inc. stock quote today ?
Pfizer Inc. stock price is $27.87 today.
Is Pfizer Inc. stock public?
Yes, Pfizer Inc. is a publicly traded company.